- Board of Trustees at the University of North Carolina at Chapel Hill
Haywood was originally selected as an independent board member of Dara Biosciences in 2008 and rose to be the Board Chair until the company was bought by Mida Tech Pharma in 2015. Before that he was a director and Vice-Chair for I-Trax Inc. before it was acquired by Walgreens in 2008. Prior to I-Trax, he was CEO of CHD Meridan Corporate Healthcare for five years until it was acquired by I-Trax in 2004. Earlier in his career he served as Executive Vice President and CFO of Lab Corp of America, CEO of Allied Clinical Laboratories and VP of Finance and COO of Roche Biomedical Laboratories. He started his career with Wachovia Bank & Trust.
He has served in numerous roles within the University of North Carolina community, currently as Vice Chair of the Board of Trustees. He is a board member of the Carolina Research Venture Fund, UNC-Chapel Hill Foundation, Inc., the UNC Foundation Investment Fund, Inc., the Endowment Fund of UNC-CH and the Chapel Hill Real Estate Holdings, Inc.
His career has included a number roles as a board member for many public and private companies including Tripath Imaging, Inc.(diagnostics), EV3, Inc. (cardiology), American Esoterics, Inc., JDN Realty, Inc. (real estate development), Sonus Corp. (audiology), Unilab, Inc. (clinical labs), Ameripath, Inc. (anatomic labs) and Beamon Corp. (construction). He received his undergraduate BA degree from the University of North Carolina at Chapel Hill.